Get to know our clinical trials
Phase III, multicenter, open-label, randomized, open-label clinical trial to evaluate RMC-6236 in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDCA).
THE PURPOSE OF A TRIAL IS TO COLLECT INFORMATION ABOUT THE INVESTIGATIONAL DRUG: RMC-6236
Technical Summary
- PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE RMC-6236 VS. INVESTIGATOR'S CHOICE OF REFERENCE THERAPY IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDCA).
- Code EudraCT: 2024-516063-89
- Protocol number: RMC-6236-302
- Promoter: Revolution Medicines, Inc.
- Molecule/Drug: RMC-6236
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.